82 related articles for article (PubMed ID: 9516965)
1. A sensitive and specific radioimmunoassay for LY309887, a potent inhibitor of glycinamide ribonucleotide formyltransferase.
Coleman DL; Canak N; Place GD; Shih C; Bowsher RR
Clin Cancer Res; 1998 Jan; 4(1):157-63. PubMed ID: 9516965
[TBL] [Abstract][Full Text] [Related]
2. Cellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell lines.
Lu X; Errington J; Chen VJ; Curtin NJ; Boddy AV; Newell DR
Clin Cancer Res; 2000 Jan; 6(1):271-7. PubMed ID: 10656458
[TBL] [Abstract][Full Text] [Related]
3. Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol.
Mendelsohn LG; Shih C; Schultz RM; Worzalla JF
Invest New Drugs; 1996; 14(3):287-94. PubMed ID: 8958184
[TBL] [Abstract][Full Text] [Related]
4. Whole-body disposition and polyglutamate distribution of the GAR formyltransferase inhibitors LY309887 and lometrexol in mice: effect of low-folate diet.
Habeck LL; Chay SH; Pohland RC; Worzalla JF; Shih C; Mendelsohn LG
Cancer Chemother Pharmacol; 1998; 41(3):201-9. PubMed ID: 9443636
[TBL] [Abstract][Full Text] [Related]
5. Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.
Chen VJ; Bewley JR; Andis SL; Schultz RM; Iversen PW; Shih C; Mendelsohn LG; Seitz DE; Tonkinson JL
Br J Cancer; 1998; 78 Suppl 3(Suppl 3):27-34. PubMed ID: 9717988
[TBL] [Abstract][Full Text] [Related]
6. Tight binding of folate substrates and inhibitors to recombinant mouse glycinamide ribonucleotide formyltransferase.
Sanghani SP; Moran RG
Biochemistry; 1997 Aug; 36(34):10506-16. PubMed ID: 9265631
[TBL] [Abstract][Full Text] [Related]
7. A novel class of monoglutamated antifolates exhibits tight-binding inhibition of human glycinamide ribonucleotide formyltransferase and potent activity against solid tumors.
Habeck LL; Leitner TA; Shackelford KA; Gossett LS; Schultz RM; Andis SL; Shih C; Grindey GB; Mendelsohn LG
Cancer Res; 1994 Feb; 54(4):1021-6. PubMed ID: 8313357
[TBL] [Abstract][Full Text] [Related]
8. Rational design, synthesis, evaluation, and crystal structure of a potent inhibitor of human GAR Tfase: 10-(trifluoroacetyl)-5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic acid.
Zhang Y; Desharnais J; Marsilje TH; Li C; Hedrick MP; Gooljarsingh LT; Tavassoli A; Benkovic SJ; Olson AJ; Boger DL; Wilson IA
Biochemistry; 2003 May; 42(20):6043-56. PubMed ID: 12755606
[TBL] [Abstract][Full Text] [Related]
9. Sensitive and specific radioimmunoassay for fialuridine: initial assessment of pharmacokinetics after single oral doses to healthy volunteers.
Bowsher RR; Compton JA; Kirkwood JA; Place GD; Jones CD; Mabry TE; Hyslop DL; Hatcher BL; DeSante KA
Antimicrob Agents Chemother; 1994 Sep; 38(9):2134-42. PubMed ID: 7811032
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of 10-methanesulfonyl-DDACTHF, 10-methanesulfonyl-5-DACTHF, and 10-methylthio-DDACTHF as potent inhibitors of GAR Tfase and the de novo purine biosynthetic pathway.
Cheng H; Chong Y; Hwang I; Tavassoli A; Zhang Y; Wilson IA; Benkovic SJ; Boger DL
Bioorg Med Chem; 2005 May; 13(10):3577-85. PubMed ID: 15848770
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of N-[4-[5-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-2-(2,2,2-trifluoroacetyl)pentyl]benzoyl]-L-glutamic acid as a potential inhibitor of GAR Tfase and the de novo purine biosynthetic pathway.
Cheng H; Hwang I; Chong Y; Tavassoli A; Webb ME; Zhang Y; Wilson IA; Benkovic SJ; Boger DL
Bioorg Med Chem; 2005 May; 13(10):3593-9. PubMed ID: 15848772
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of alpha- and gamma-carboxamide derivatives of 10-CF3CO-DDACTHF.
Chong Y; Hwang I; Tavassoli A; Zhang Y; Wilson IA; Benkovic SJ; Boger DL
Bioorg Med Chem; 2005 May; 13(10):3587-92. PubMed ID: 15848771
[TBL] [Abstract][Full Text] [Related]
13. A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.
Laohavinij S; Wedge SR; Lind MJ; Bailey N; Humphreys A; Proctor M; Chapman F; Simmons D; Oakley A; Robson L; Gumbrell L; Taylor GA; Thomas HD; Boddy AV; Newell DR; Calvert AH
Invest New Drugs; 1996; 14(3):325-35. PubMed ID: 8958188
[TBL] [Abstract][Full Text] [Related]
14. Radioimmunoassay and pharmacokinetic profile of bupropion in the dog.
Butz RF; Schroeder DH; Welch RM; Mehta NB; Phillips AP; Findlay JW
J Pharmacol Exp Ther; 1981 Jun; 217(3):602-10. PubMed ID: 6785419
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10- dideaza-5,6,7,8-tetrahydrofolic acid (Lometrexol) administered with an oral folic acid supplement.
Wedge SR; Laohavinij S; Taylor GA; Boddy A; Calvert AH; Newell DR
Clin Cancer Res; 1995 Dec; 1(12):1479-86. PubMed ID: 9815947
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034.
McLeod HL; Cassidy J; Powrie RH; Priest DG; Zorbas MA; Synold TW; Shibata S; Spicer D; Bissett D; Pithavala YK; Collier MA; Paradiso LJ; Roberts JD
Clin Cancer Res; 2000 Jul; 6(7):2677-84. PubMed ID: 10914709
[TBL] [Abstract][Full Text] [Related]
17. Purification and partial characterization of feline alpha1-proteinase inhibitor (falpha1-PI) and the development and validation of a radioimmunoassay for the measurement of falpha1-PI in serum.
Fetz K; Ruaux CG; Steiner JM; Suchodolski JS; Williams DA
Biochimie; 2004 Jan; 86(1):67-75. PubMed ID: 14987802
[TBL] [Abstract][Full Text] [Related]
18. An inhibitor of glycinamide ribonucleotide formyltransferase is selectively cytotoxic to cells that lack a functional G1 checkpoint.
Zhang CC; Boritzki TJ; Jackson RC
Cancer Chemother Pharmacol; 1998; 41(3):223-8. PubMed ID: 9443639
[TBL] [Abstract][Full Text] [Related]
19. A multisubstrate adduct inhibitor of AICAR transformylase.
Wall M; Shim JH; Benkovic SJ
J Med Chem; 1999 Sep; 42(18):3421-4. PubMed ID: 10479275
[No Abstract] [Full Text] [Related]
20. Novel nonclassical inhibitors of glycinamide ribonucleotide formyltransferase: 10-formyl and 10-hydroxymethyl derivatives of 5,8,10-trideazapteroic acid.
Liu L; Nair MG; Kisliuk RL
J Mol Recognit; 1996; 9(2):169-74. PubMed ID: 8877810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
